DYN
Closed
Dyne Therapeutics inc
8.68
-0.84 (-8.82%)
Last Update: 01 Jul 2025 23:19:00
Yesterday: 9.52
Day's Range: 8.41 - 9.23
Send
sign up or login to leave a comment!
When Written:
11.52
Dyne Therapeutics Inc. is a biotechnology company that was founded in 2017 and is headquartered in Waltham, Massachusetts. The company is focused on developing therapies for patients with serious muscle diseases by using its proprietary technology platform called "PoloBiologic". This platform is designed to enable the delivery of oligonucleotides, which are short DNA or RNA molecules, to muscle tissues.
Dyne Therapeutics is currently focused on developing treatments for patients with myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). These are both rare genetic disorders that cause progressive muscle weakness and wasting.
The company has raised over $300 million in funding from various investors, including pharmaceutical companies, venture capital firms, and institutional investors. Dyne Therapeutics has also established collaborations with other biotech companies and academic institutions to advance its research and development efforts.
Dyne Therapeutics is led by an experienced management team, including its CEO, Joshua Brumm, who has over 20 years of experience in the biotechnology industry. The company's board of directors includes industry veterans and experts in drug development and commercialization.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Dyne Therapeutics is currently focused on developing treatments for patients with myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). These are both rare genetic disorders that cause progressive muscle weakness and wasting.
The company has raised over $300 million in funding from various investors, including pharmaceutical companies, venture capital firms, and institutional investors. Dyne Therapeutics has also established collaborations with other biotech companies and academic institutions to advance its research and development efforts.
Dyne Therapeutics is led by an experienced management team, including its CEO, Joshua Brumm, who has over 20 years of experience in the biotechnology industry. The company's board of directors includes industry veterans and experts in drug development and commercialization.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!